MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Altimmune ROCE Ratio 2011-2026 | ALT
Annual ROCE Ratio Altimmune
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80.08 | -48.33 | -46.21 | -48.67 | -23.51 | -40.82 | -35.63 | -27.24 | -56.6 | -4.84 | -52.54 | -104.79 | -41.08 | -64.47 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.84 | -104.79 | -48.2 |
Quarterly ROCE Ratio Altimmune
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47.38 | -50.37 | -67.28 | -34.7 | -49.68 | -46.88 | -40.71 | -38.7 | -50.77 | -47.85 | -47.6 | -33.1 | -48.97 | -52.77 | -52.59 | -32.2 | -40.32 | -32.56 | -30.41 | -19.5 | -44.27 | -60.92 | -60.57 | -37.68 | -46.08 | -29.72 | -33.17 | -32.06 | -110.63 | -180.79 | -179.73 | -100.22 | -117.33 | -53.63 | -48.43 | -43.41 | -28.47 | -23.56 | -30.39 | -16.97 | -29.15 | -41.05 | -35.65 | -55.77 | -110.49 | -132.24 | -146.03 | -147.76 | -90.9 | -62.63 | -54.92 | -53.68 | -48.28 | -52.01 | -58.96 | -73.97 | -19.06 | -19.44 | -28.64 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -16.97 | -180.79 | -57.68 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
14.97 | $ 20.13 | -2.75 % | $ 2.54 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-188.87 | $ 163.18 | -1.92 % | $ 8.12 B | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.64 | -4.84 % | $ 1.09 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
14.24 | $ 8.37 | -4.12 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
27.01 | $ 23.82 | -0.25 % | $ 2.91 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Corvus Pharmaceuticals
CRVS
|
-60.51 | $ 17.04 | -4.75 % | $ 818 M | USA |
 |
Champions Oncology
CSBR
|
120.71 | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Daré Bioscience
DARE
|
390.07 | $ 1.59 | -1.27 % | $ 13.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-337.72 | $ 21.94 | -5.66 % | $ 2.13 B | France |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-87.67 | $ 25.4 | -5.44 % | $ 680 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-7.7 | $ 17.58 | -3.14 % | $ 451 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 40.7 | -0.8 % | $ 11.1 B | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
-66.13 | $ 7.91 | -3.77 % | $ 210 M | USA |
 |
Amicus Therapeutics
FOLD
|
11.96 | $ 14.35 | -0.1 % | $ 4.43 B | USA |
 |
Galectin Therapeutics
GALT
|
40.49 | $ 2.95 | -3.59 % | $ 184 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 32.63 | -4.28 % | $ 2.69 B |  Belgium |
 |
Codexis
CDXS
|
-87.44 | $ 0.98 | -3.85 % | $ 71.9 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-631.87 | $ 26.25 | -4.16 % | $ 342 M | USA |
|
Galecto
GLTO
|
-123.43 | $ 28.88 | -3.91 % | $ 767 M |  Danmark |
 |
Genmab A/S
GMAB
|
31.74 | $ 27.42 | -7.52 % | $ 17.6 B | Danmark |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Gossamer Bio
GOSS
|
-292.75 | $ 0.44 | 3.03 % | $ 67.2 M | USA |
 |
GeoVax Labs
GOVX
|
-464.02 | $ 1.52 | -2.88 % | $ 2.76 M | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.51 | -6.38 % | $ 6.83 B |  Spain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
99.51 | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Halozyme Therapeutics
HALO
|
960.8 | $ 68.8 | -1.5 % | $ 8.24 B | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-39.57 | $ 28.35 | -2.91 % | $ 1.64 B | USA |
 |
Hoth Therapeutics
HOTH
|
-119.38 | $ 0.98 | -3.92 % | $ 6.25 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |